Opdivo® (nivolumab) – Expanded indication
August 20, 2021 - Bristol Myers Squibb announced the FDA approval of Opdivo (nivolumab), for the adjuvant treatment of patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC.
Download PDF
